DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Copyrighted Material INDEX Aarskog syndrome, 1–8 manifestations and management, albinism, 47 dental anomalies, 5–6 11–27 Costello syndrome, 225, 226 development and behavior problems, 5 musculoskeletal anomalies, 22–26 Down syndrome, 366 diagnostic criteria, 1–2 neurological anomalies, 17–20 Wolf–Hirschhorn syndrome, diagnostic testing, 4 respiratory anomalies, 20–21 270, 275 differential diagnosis, 4 Acrocallosal syndrome, differential diagnosis, Aicardi syndrome, differential diagnosis, deletion fetal anticonvulsant syndrome, 428 Greig cephalopolysyndactyly 1p36 syndrome, 255 Noonan syndrome, 654 syndrome, 710 Airway obstruction: etiology, pathogenesis, and genetics, 3–4 Acrofacial dysostoses, Nager syndrome, 809 Robin sequence, 807, 808 genital abnormalities, 6–7 Action myoclonus‐renal failure syndrome, 343 Stickler syndrome, 921 growth and feeding problems, 4–5 ACVRL1 gene mutation, hereditary hemorrhagic Treacher Collins syndrome, 931 incidence, 1 telangiectasia, 476 trisomy 13 and 18 syndromes, 952 manifestations and management, 4–7 ADAMTS2 gene, Ehlers–Danlos syndromes, 397 Alagille syndrome, 31–44 musculoskeletal anomalies, 6 Adaptive function: cardiovascular anomalies, 38–40 neurological anomalies, 6 Down syndrome, 363 development and behavior problems, 36 ophthalmologic anomalies, 5 fetal alcohol spectrum disorders, 413 diagnostic criteria, 32–34 Abnormal spontaneous brainstem activation, 801 fetal anticonvulsant syndrome, 431 diagnostic testing, 35 Acanthosis nigricans: 48,XXYY syndrome, 553 differential diagnosis, 35–36 achondroplasia, 11 Smith–Magenis syndrome, 873–874 deletion 22q11.2 syndrome, 298 Costello syndrome, 236 velo‐cardio‐facial syndrome, 300 etiology, pathogenesis, and genetics, 34–36 N‐acetylcysteine, Prader–Willi syndrome, 756 Adrenal insufficiency: genetic counseling, 35 Achondrogenesis type I, differential diagnosis, holoprosencephaly, 498 genitourinary anomalies, 40 osteogenesis imperfecta, 693 Pallister–Hall syndrome, 711 growth and feeding problems, 36 Achondroplasia, 9–30 Prader–Willi syndrome, 750, 751 incidence, 31–32 dental anomalies, 26 Adrenarche: manifestations and management, 36–41 development and behavior problems, 16–17COPYRIGHTEDATR‐X syndrome, 101 MATERIALmusculoskeletal anomalies, 40–41 diagnostic criteria, 9–10 Prader–Willi syndrome, 736 ophthalmologic anomalies, 40 diagnostic testing, 11 Silver–Russell syndrome, 844–845 Albinism, 45–59 differential diagnosis, 11 Smith–Magenis syndrome, 886 dermatologic anomalies, 50–52 ear anomalies, 21 Adrenocorticotropic hormone (ACTH): development and behavior problems, 50 etiology, pathogenesis, and genetics, 10–11 inverted duplicated chromosome 15 diagnostic criteria, 46–47 growth and feeding problems, 12–16 syndrome, 523 diagnostic testing, 47–49 hearing disorders, 21 Pallister–Hall syndrome, 711 differential diagnosis, 50 incidence, 9 Aging, premature: etiology, pathogenesis, and genetics, 47 Cassidy and Allanson’s Management of Genetic Syndromes, Fourth Edition. Edited by John C. Carey, Agatino Battaglia, David Viskochil, and Suzanne B. Cassidy. © 2021 John Wiley & Sons, Inc. Published 2021 by John Wiley & Sons, Inc. 1039 0004944829.INDD 1039 9/25/2020 7:13:41 AM 1040 INDEX Albinism (cont’d) Angelman syndrome, 61–73 Aortic dilatation: gastrointestinal anomalies, 55 development and behavior problems, 66–69 in deletion 22q11.2 syndrome, 304 hearing disorders, 48 diagnostic criteria, 61 in hereditary hemorrhagic telangiectasia, 475 hematologic disorders, 53–54 diagnostic testing, 64–65 in Marfan syndrome, 577, 579, 581, 589, 593 incidence, 45–46 differential diagnosis, 65–66 in Pallister–Killian syndrome, 727 manifestations and management, 50–55 ATR‐X syndrome, 98, 99 in Sotos syndrome, 909 ophthalmologic anomalies, 52–53 deletion 1p36 syndrome, 255 in Turner syndrome, 981, 983 pulmonic anomalies, 54 deletion 5p syndrome, 283 Apert syndrome: Albright hereditary osteodystrophy, differential deletion 22q13 syndrome, 321 cardiovascular anomalies, 249 diagnosis, Prader–Willi syndrome, 741 inverted duplicated chromosome 15 development and behavior Alcohol consumption, fetal alcohol spectrum syndrome, 518 problems, 247 disorders, 405–424 Mowat–Wilson syndrome, 601 diagnostic criteria, 241–242 Allelic conditions: Rett syndrome, 797 diagnostic testing, 246 ATR‐X syndrome, 94–95 etiology, pathogenesis, and genetics, 61–62 etiology, pathogenesis, and genetics, 245 Juberg–Marsidi syndrome, 102 genetic counseling, 65 genitourinary anomalies, 250 Allelic pleiotropic developmental anomaly growth and feeding problems, 66 otolaryngologic anomalies, 248 syndromes: incidence, 61 skeletal anomalies, 249 Greig cephalopolysyndactyly syndrome, language difficulties, 67 Apneic deaths: 707–716 manifestations and management, 66–70 achondroplasia, 18, 19 Pallister–Hall syndrome, 707–716 musculoskeletal anomalies, 70 Turner syndrome, 982 Alobar holoprosencephaly, 487 neurological anomalies, 69–70 Apolipoprotein E (APOE gene), Down syndrome craniofacial anomalies, 497 ophthalmologic anomalies, 70 and Alzheimer disease, 359 development and behavior problems, Angiofibromas, tuberous sclerosis complex, 968 Arachnodactyly, Marfan syndrome, 588 495–496 Angiomyolipomas, tuberous sclerosis complex, Arachnoid cysts, Phelan–McDermid diagnostic criteria, 488 959, 970, 972 syndrome, 326 diagnostic testing, 494 Angiotensin‐converting enzyme (ACE) inhibitors, ARID1A gene mutations, Coffin–Siris etiology, pathogenesis, and genetics, 492 Marfan syndrome, 589, 593 syndrome, 189 incidence, 487–488 Angiotensin receptor blockers, Loeys–Dietz ARID1B gene mutations, Coffin–Siris syndrome, neurological anomalies, 498–499 syndrome, 566, 571 185, 189 Alopecia: Aniridia: Array comparative genomic hybridization Costello syndrome, 226, 236 aniridia associated keratopathy, 345 (aCGH): Down syndrome, 378 WAGR syndrome, 336, 342 ATR‐X syndrome, 97 incontinentia pigmenti, 509, 510 ANKRD11 gene Cornelia de Lange syndrome, 211 Cohen syndrome, 199 myotonic dystrophy type 1, 622 Anorectal anomalies: Cornelia de Lange syndrome, 212 Pallister–Killian syndrome, 718 Kabuki syndrome, 535 Pallister–Killian syndrome, 722 Turner syndrome, 990 Pallister–Killian syndrome, 727 Arrhythmias: Alstrom syndrome differential diagnosis: VATER/VACTERL association, 1000, 1001 Costello syndrome, 232 Bardet–Biedl syndrome, 112 Anosmia: myotonic dystrophy type 1, 621 Cohen syndrome, 199 Bardet–Biedl syndrome, 118 Noonan syndrome, 658 Alzheimer disease Down syndrome, 359, 365 CHARGE syndrome, 160, 161, 166 Arterial tortuosity syndrome: Amsterdam dwarfism. See Cornelia de Lange holoprosencephaly, 493 differential diagnosis syndrome Antiepileptics/anticonvulsants: Loeys–Dietz syndrome, 568 Amyloid precursor protein (APP) gene: fetal anticonvulsant syndrome, 425, 432 Marfan syndrome, 585 Down syndrome and Alzheimer disease, 365 fragile X syndrome, 450 Arteriohepatic dysplasia. See Alagille syndrome: fragile‐X syndrome, 443 Robin sequence, 811 Arthritis. See also Osteoarthritis: Amyoplasia arthrogryposis, 75, 77, 79–85 Smith–Magenis syndrome, 877 arthrogryposis, 85 Androgen replacement therapy: tuberous sclerosis complex, 967 Stickler syndrome, 922 49,XXXXY syndrome, 559 Antihistamines, Alagille syndrome, 37 Arthrogryposis, 75–91 Klinefelter syndrome, 550 Anti‐hypertensives: development and behavior problems, 84–85 Anemia: Loeys‐Dietz syndrome, 571 diagnostic criteria, 75–76 ATR‐X syndrome, 93, 101 Marfan syndrome, 593 diagnostic testing, 77 Cohen syndrome, 202 Anti‐RANK ligand antibody, osteogenesis differential diagnosis, 79 Cornelia de Lange syndrome, 217, 219 imperfecta, 697 ear anomalies, 88 Denys–Drash syndrome, 343 Anxiety: etiology, pathogenesis, and genetics, 77 Down syndrome, 379 Costello syndrome, 232 growth and feeding problems, 79–84 hereditary hemorrhagic telangiectasia, 478 Down syndrome, 364 hearing disorders, 88 Noonan syndrome, 660 fetal alcohol spectrum disorders, 415 incidence, 75 Proteus syndrome, 769 fragile X syndrome, 445 manifestations and management, 79–88 VATER/VACTERL association, 997 Klinefelter syndrome, 556 musculoskeletal anomalies, 85–87 Anesthesia risks: Noonan syndrome, 657 neurological anomalies, 87 achondroplasia, 26 Prader–Willi syndrome, 745 ophthalmologic anomalies, 87 myotonic dystrophy type 1, 624 Williams syndrome, 1026 respiratory anomalies, 87–88 Prader–Willi syndrome, 756 Aortic coarctation: Aryl hydrocarbon receptor nuclear translocator Rubinstein–Taybi syndrome, 832 neurofibromatosis type 1, 645 (ARNT), von Hippel–Lindau Treacher Collins syndrome, 933 Turner syndrome, 981 syndrome, 1006 0004944829.INDD 1040 9/25/2020 7:13:41 AM INDEX 1041 Assisted reproductive technology: Costello syndrome, 232 Stickler syndrome, 918 Beckwith–Wiedemann syndrome, 131 deletion 5p syndrome, 284 Back pain: Turner syndrome, 984–985 Down syndrome, 364 Loeys–Dietz syndrome, 570 Asthenic body habitus, Marfan syndrome, 587 fetal valproate syndrome, 431 Marfan syndrome, 587, 588, 591 ASXL1 gene mutations, Bohring–Opitz fragile X syndrome, 447 osteogenesis imperfecta, 694 syndrome, 212 inverted duplicated chromosome 15 syndrome, Sotos syndrome, 910 Ataxia: 517, 520–521 Bannayan–Riley–Ruvalcaba syndrome: Angelman syndrome, 64, 66 Kabuki syndrome, 532 development and behavior problems, 782 Bardet–Biedl syndrome, 118 Klinefelter syndrome, 545 diagnostic criteria, 776–777 deletion 22q11.2 syndrome, 304 myotonic dystrophy type 1, 618 diagnostic testing, 779 fragile X syndrome, 443, 445, 450 neurofibromatosis type 1, 632, 637 differential diagnosis, hereditary hemorrhagic Gorlin syndrome, 464 Noonan syndrome, 656 telangiectasia,
Load more

Recommended publications
  • Genetic Syndromes with an Increased Risk of Developing Cancer As an Example of the Use of New Technologies
    Genetics and Molecular Biology, 37, 1 (suppl), 241-249 (2014) Copyright © 2014, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Review Article Impact of NGS in the medical sciences: Genetic syndromes with an increased risk of developing cancer as an example of the use of new technologies Pablo Lapunzina1,2, Rocío Ortiz López3,4, Lara Rodríguez-Laguna2, Purificación García-Miguel5, Augusto Rojas Martínez3,4 and Víctor Martínez-Glez1,2 1Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. 2Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 3Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León. Monterrey, Nuevo León, México. 4Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México. 5Unidad de Oncología Pediátrica, Hospital Infantil La Paz, Madrid, Spain. Abstract The increased speed and decreasing cost of sequencing, along with an understanding of the clinical relevance of emerging information for patient management, has led to an explosion of potential applications in healthcare. Cur- rently, SNP arrays and Next-Generation Sequencing (NGS) technologies are relatively new techniques used to scan genomes for gains and losses, losses of heterozygosity (LOH), SNPs, and indel variants as well as to perform com- plete sequencing of a panel of candidate genes, the entire exome (whole exome sequencing) or even the whole ge- nome. As a result, these new high-throughput technologies have facilitated progress in the understanding and diagnosis of genetic syndromes and cancers, two disorders traditionally considered to be separate diseases but that can share causal genetic alterations in a group of developmental disorders associated with congenital malformations and cancer risk.
    [Show full text]
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al
    US 20160281 166A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE et al. (43) Pub. Date: Sep. 29, 2016 (54) METHODS AND SYSTEMIS FOR SCREENING Publication Classification DISEASES IN SUBJECTS (51) Int. Cl. (71) Applicant: PARABASE GENOMICS, INC., CI2O I/68 (2006.01) Boston, MA (US) C40B 30/02 (2006.01) (72) Inventors: Arindam BHATTACHARJEE, G06F 9/22 (2006.01) Andover, MA (US); Tanya (52) U.S. Cl. SOKOLSKY, Cambridge, MA (US); CPC ............. CI2O 1/6883 (2013.01); G06F 19/22 Edwin NAYLOR, Mt. Pleasant, SC (2013.01); C40B 30/02 (2013.01); C12O (US); Richard B. PARAD, Newton, 2600/156 (2013.01); C12O 2600/158 MA (US); Evan MAUCELI, (2013.01) Roslindale, MA (US) (21) Appl. No.: 15/078,579 (57) ABSTRACT (22) Filed: Mar. 23, 2016 Related U.S. Application Data The present disclosure provides systems, devices, and meth (60) Provisional application No. 62/136,836, filed on Mar. ods for a fast-turnaround, minimally invasive, and/or cost 23, 2015, provisional application No. 62/137,745, effective assay for Screening diseases, such as genetic dis filed on Mar. 24, 2015. orders and/or pathogens, in Subjects. Patent Application Publication Sep. 29, 2016 Sheet 1 of 23 US 2016/0281166 A1 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS S{}}\\93? sau36 Patent Application Publication Sep. 29, 2016 Sheet 2 of 23 US 2016/0281166 A1 &**** ? ???zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz??º & %&&zzzzzzzzzzzzzzzzzzzzzzz &Sssssssssssssssssssssssssssssssssssssssssssssssssssssssss & s s sS ------------------------------ Patent Application Publication Sep. 29, 2016 Sheet 3 of 23 US 2016/0281166 A1 23 25 20 FG, 2. Patent Application Publication Sep. 29, 2016 Sheet 4 of 23 US 2016/0281166 A1 : S Patent Application Publication Sep.
    [Show full text]
  • 2012 2013 Causes of Birth Defects: Lessons from History 1 0 Drug
    cited Issue title 2012 2013 Vol.51 NO1 Causes of birth defects: Lessons from history 1 0 (2011) Drug safety in pregnancy: Utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information 3 0 Services Role of rare cases in deciphering the mechanisms of congenital 2 0 anomalies: CHARGE syndrome research Value of the small cohort study including a physical examination 2 0 for minor structural defects in identifying new human teratogens In vitro models of pancreatic differentiation using embryonic stem 2 1 or induced pluripotent stem cells Peptic ulcer disease with related drug treatment in pregnant 0 0 women and congenital abnormalities in their offspring Efficacy of medical care of epileptic pregnant women based on the 1 0 rate of congenital abnormalities in their offspring Rare clinical entity Perlman syndrome: Is cholestasis a new 0 0 finding? An unusual bronchopulmonary malformation in adulthood: Bronchial 0 0 atresia Vol.51 NO2 Effects of melanocortins on fetal development 0 0 (2011) Hypothyroidism caused by phenobarbital affects patterns of 0 0 estrous cyclicity in rats Adrenocorticotropic tumor cells transplanted into mouse embryos 0 0 affect pancreatic histogenesis Distribution of the longevity gene product, SIRT1, in developing 1 1 mouse organs Is there a reduction of congenital abnormalities in the offspring of diabetic pregnant women after folic acid supplementation? A 3 0 population-based case-control study Analysis of genitourinary anomalies in patients with VACTERL (Vertebral anomalies,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • Tumor in Patients with 9Q22.3 Microdeletion Syndrome Suggests a Role for PTCH1 in Nephroblastomas
    European Journal of Human Genetics (2013) 21, 784–787 & 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13 www.nature.com/ejhg SHORT REPORT Wilms’ tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas Bertrand Isidor*,1,2,14, Franck Bourdeaut3,4,5,14, Delfine Lafon6, Ghislaine Plessis7, Elodie Lacaze7, Caroline Kannengiesser8, Sylvie Rossignol9, Olivier Pichon1, Annaig Briand1, Dominique Martin-Coignard10, Maria Piccione11, Albert David1, Olivier Delattre2,Ce´cile Jeanpierre12, Nicolas Se´venet6 and Ce´dric Le Caignec1,13 Nephroblastoma (Wilms’ tumor; WT) is the most common renal tumor of childhood. To date, several genetic abnormalities predisposing to WT have been identified in rare overgrowth syndromes. Among them, abnormal methylation of the 11p15 region, GPC3 and DIS3L2 mutations, which are responsible for Beckwith–Wiedemann, Simpson–Golabi–Behmel and Perlman syndromes, respectively. However, the underlying cause of WT remains unknown in the majority of cases. We report three unrelated patients who presented with WT in addition to a constitutional 9q22.3 microdeletion and dysmorphic/overgrowth syndrome. The size of the deletions was variable (ie, from 1.7 to 8.9 Mb) but invariably encompassed the PTCH1 gene. Subsequently, we identified a somatic PTCH1 nonsense mutation in the renal tumor of one patient. In addition, by array comparative genomic hybridization method, we analyzed the DNA extracted from the blood samples of nine patients with overgrowth syndrome and WT, but did not identify any deleterious chromosomal imbalances in these patients. These findings strongly suggest that patients with constitutional 9q22.3 microdeletion have an increased risk of WT, and that PTCH1 have a role in the pathogenesis of nephroblastomas.
    [Show full text]
  • Beckwith-Wiedemann Syndrome
    560 Med Genet 1994;31:560-564 Syndrome of the month J Med Genet: first published as 10.1136/jmg.31.7.560 on 1 July 1994. Downloaded from Beckwith-Wiedemann syndrome Margaret Elliott, Eamonn R Maher In 1963 Beckwith' presented the necropsy find- features are most apparent before the age of 3 ings of three unrelated children with exompha- years, and after the age of 5 years there is often los, macroglossia, hyperplasia of the kidneys only minor dysmorphism. It is helpful to con- and pancreas, and adrenal cytomegaly, and sug- sider the complications of BWS by the age at gested that this might represent a new syn- presentation. drome. In 1964 Wiedemann2 published a case report of three sibs with exomphalos, macrog- lossia, and overgrowth. Subsequently more PRENATAL than 300 cases have been reported and the Exomphalos complicates approximately half incidence of Beckwith-Wiedemann syndrome the cases of BWS and will usually be picked up (BWS) has been estimated at 007 per 1000 on prenatal ultrasonography, but BWS is a births.34 rare cause of exomphalos (< 3% of all cases).6 Prenatal diagnosis of BWS has occasionally been reported after ultrasonographic detection Clinical features and natural history of a combination of abdominal wall defect, The clinical features of BWS are listed in the polyhydramnios, nephromegaly, and macro- table which is derived from the personal experi- glossia.7 BWS pregnancies are frequently com- ence of one of the authors (ME) of 69 cases in plicated by premature onset of labour. The risk the UK and 22 cases from the one other large of prematurity is associated with an increased clinical study published.5 Anterior abdominal incidence of polyhydramnios but not with fetal wall defects, macroglossia, pre- or postnatal overgrowth alone.
    [Show full text]
  • Cancer Prone Disease Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Cancer Prone Disease Section Mini Review Perlman syndrome (renal hamartomas, nephroblastomatosis and fetal gigantism) Maria Piccione, Giovanni Corsello Dipartimento Materno-Infantile University of Palermo, Palermo, Italy Published in Atlas Database: December 2006 Online updated version: http://AtlasGeneticsOncology.org/Kprones/PerlmanID10117.html DOI: 10.4267/2042/38420 This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. © 2007 Atlas of Genetics and Cytogenetics in Oncology and Haematology Etiology: The genetic basis of the Perlman syndrome is Identity unknown and there is no conclusive laboratory test to Note: The Perlman syndrome is characterized by confirm the diagnosis. Although both sexes are polyhydramnios, fetal overgrowth, neonatal affected, the sex ratio is 2M:1F. The diagnosis is based macrosomia, high neonatal mortality, macrocephaly, on characteristic features and confirmed by histological dysmorphic facial features, visceromegaly, renal evidence. The syndrome has been described in nephroblastomatosis and a predisposition for Wilms both consanguineous and non-consanguineous tumor at very early age. couplings. Inheritance: Inheritance is of an autosomal recessive nature. Figure 1,2 : Macrocephaly, hypertelorism, epicanthus, broad flat nasal bridge, anteverted upper lip, axial hypotonia. Atlas Genet Cytogenet Oncol Haematol. 2007;11(2) 136 Perlman syndrome (renal hamartomas, nephroblastomatosis and fetal gigantism) Piccione M, Corsello G Figure 3 : Abdominal ultrasound scan at 6 months of age: nephromegaly with lobulated contoured kidneys and loss of corticomedullary differentiation. - Cardiomegaly. Clinics - Congenital heart disease: interrupted aortic arch and Phenotype and clinics anomalous coronary vessels and the dextroposition of the heart, muscular ventricular septal defect.
    [Show full text]
  • Syndromes and Constitutional Chromosomal Abnormalities
    Downloaded from jmg.bmj.com on May 16, 2013 - Published by group.bmj.com 705 REVIEW Syndromes and constitutional chromosomal abnormalities associated This article is available free on JMG online via the JMG Unlocked open access trial, with Wilms tumour funded by the Joint Information Systems Committee. For further information, see R H Scott, C A Stiller, L Walker, N Rahman http://jmg.bmjjournals.com/cgi/content/ full/42/2/97 ............................................................................................................................... J Med Genet 2006;43:705–715. doi: 10.1136/jmg.2006.041723 Wilms tumour has been reported in association with over Multiple nephrogenic rests throughout the kid- ney are sometimes present and can be referred to 50 different clinical conditions and several abnormal as nephroblastomatosis. constitutional karyotypes. Conclusive evidence of an The dramatic advances in the treatment of increased risk of Wilms tumour exists for only a minority of Wilms tumour are such that long term survival is now the norm: exceeding 90% for disease these conditions, including WT1 associated syndromes, localised to the abdomen (stages 1–3), and over familial Wilms tumour, and certain overgrowth conditions 70% in metastatic disease (stage 4).7 The treat- such as Beckwith-Wiedemann syndrome. In many reported ment of Wilms tumour is determined both by stage and histological classification of the conditions the rare co-occurrence of Wilms tumour is tumour, with treatment protocols varying probably due to chance. However, for several conditions between countries. Surgical resection is comple- the available evidence cannot either confirm or exclude an mented in the majority of individuals by chemo- therapy. Currently in the United Kingdom increased risk, usually because of the rarity of the around 30% of individuals with Wilms tumour syndrome.
    [Show full text]
  • Differential Diagnoses of Overgrowth Syndromes: the Most Important Clinical and Radiological Disease Manifestations
    Hindawi Publishing Corporation Radiology Research and Practice Volume 2014, Article ID 947451, 7 pages http://dx.doi.org/10.1155/2014/947451 Review Article Differential Diagnoses of Overgrowth Syndromes: The Most Important Clinical and Radiological Disease Manifestations Letícia da Silva Lacerda,1 Úrsula David Alves,1 José Fernando Cardona Zanier,1 Dequitier Carvalho Machado,1,2 Gustavo Bittencourt Camilo,1,2 and Agnaldo José Lopes2 1 Department of Radiology, State University of Rio de Janeiro, 20551-030 Rio de Janeiro, RJ, Brazil 2 Postgraduate Programme in Medical Sciences, State University of Rio de Janeiro, 20550-170 Rio de Janeiro, RJ, Brazil Correspondence should be addressed to Agnaldo Jose´ Lopes; [email protected] Received 12 March 2014; Revised 19 May 2014; Accepted 27 May 2014; Published 9 June 2014 Academic Editor: Andreas H. Mahnken Copyright © 2014 Let´ıcia da Silva Lacerda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Overgrowth syndromes comprise a heterogeneous group of diseases that are characterized by excessive tissue development. Some of these syndromes may be associated with dysfunction in the receptor tyrosine kinase (RTK)/PI3K/AKT pathway, which results in an increased expression of the insulin receptor. In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung’s disease, and neurofibromatosis type I) and illustrated using cases from our institution. Because these syndromes have overlapping clinical manifestations and have no established genetic tests for their diagnosis, radiological methods are important contributors to the diagnosis of many of these syndromes.
    [Show full text]